JP2008545693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545693A5 JP2008545693A5 JP2008513592A JP2008513592A JP2008545693A5 JP 2008545693 A5 JP2008545693 A5 JP 2008545693A5 JP 2008513592 A JP2008513592 A JP 2008513592A JP 2008513592 A JP2008513592 A JP 2008513592A JP 2008545693 A5 JP2008545693 A5 JP 2008545693A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- omega
- subject
- acid
- choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002503 metabolic effect Effects 0.000 claims 40
- 239000002243 precursor Substances 0.000 claims 40
- 239000003814 drug Substances 0.000 claims 20
- 150000003904 phospholipids Chemical class 0.000 claims 20
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 16
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 16
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 16
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims 16
- 229940033080 omega-6 fatty acid Drugs 0.000 claims 16
- 210000004958 brain cell Anatomy 0.000 claims 14
- 210000002569 neuron Anatomy 0.000 claims 14
- 206010027175 memory impairment Diseases 0.000 claims 12
- 239000006014 omega-3 oil Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 claims 8
- 239000004381 Choline salt Substances 0.000 claims 8
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 8
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 229960001231 choline Drugs 0.000 claims 8
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 8
- 235000019417 choline salt Nutrition 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 150000003248 quinolines Chemical class 0.000 claims 8
- 238000003786 synthesis reaction Methods 0.000 claims 8
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 8
- 229940045145 uridine Drugs 0.000 claims 8
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 6
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 4
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims 4
- 208000026139 Memory disease Diseases 0.000 claims 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 4
- 235000021342 arachidonic acid Nutrition 0.000 claims 4
- 229940114079 arachidonic acid Drugs 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 4
- 229960004488 linolenic acid Drugs 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 210000000225 synapse Anatomy 0.000 claims 4
- 210000002182 synaptic membrane Anatomy 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000024571 Pick disease Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 229960001716 benzalkonium Drugs 0.000 claims 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 210000003061 neural cell Anatomy 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68335205P | 2005-05-23 | 2005-05-23 | |
| US60/683,352 | 2005-05-23 | ||
| US71607705P | 2005-09-13 | 2005-09-13 | |
| US60/716,077 | 2005-09-13 | ||
| US75505806P | 2006-01-03 | 2006-01-03 | |
| US60/755,058 | 2006-01-03 | ||
| US76175306P | 2006-01-25 | 2006-01-25 | |
| US60/761,753 | 2006-01-25 | ||
| PCT/US2006/019766 WO2006127620A2 (en) | 2005-05-23 | 2006-05-23 | Compositions containing pufa and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014088988A Division JP5823564B2 (ja) | 2005-05-23 | 2014-04-23 | Ｐｕｆａを含有する組成物及びそれを使用した方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008545693A JP2008545693A (ja) | 2008-12-18 |
| JP2008545693A5 true JP2008545693A5 (enExample) | 2009-07-09 |
| JP5566603B2 JP5566603B2 (ja) | 2014-08-06 |
Family
ID=37452701
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513596A Expired - Fee Related JP5566604B2 (ja) | 2005-05-23 | 2006-05-23 | Ｐｕｆａ及び／又はウリジンを含有する組成物及びそれを使用した方法 |
| JP2008513592A Expired - Lifetime JP5566603B2 (ja) | 2005-05-23 | 2006-05-23 | Ｐｕｆａを含有する組成物及びそれを使用した方法 |
| JP2014088988A Expired - Lifetime JP5823564B2 (ja) | 2005-05-23 | 2014-04-23 | Ｐｕｆａを含有する組成物及びそれを使用した方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513596A Expired - Fee Related JP5566604B2 (ja) | 2005-05-23 | 2006-05-23 | Ｐｕｆａ及び／又はウリジンを含有する組成物及びそれを使用した方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014088988A Expired - Lifetime JP5823564B2 (ja) | 2005-05-23 | 2014-04-23 | Ｐｕｆａを含有する組成物及びそれを使用した方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10525071B2 (enExample) |
| EP (3) | EP1888081B1 (enExample) |
| JP (3) | JP5566604B2 (enExample) |
| CN (1) | CN105663151A (enExample) |
| AU (2) | AU2006251562B2 (enExample) |
| BR (2) | BRPI0613274A2 (enExample) |
| CA (2) | CA2645645C (enExample) |
| DK (1) | DK1888081T3 (enExample) |
| ES (2) | ES2624702T5 (enExample) |
| HU (1) | HUE031206T2 (enExample) |
| NZ (3) | NZ600740A (enExample) |
| PL (1) | PL1888081T3 (enExample) |
| PT (1) | PT1888081T (enExample) |
| RU (1) | RU2603470C2 (enExample) |
| WO (2) | WO2006127627A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| AU2003299568B2 (en) * | 2002-11-27 | 2010-07-22 | Ampio Pharmaceuticals, Inc. | Treatment of diseases and conditions mediated by increased phosphorylation |
| AU2006251562B2 (en) | 2005-05-23 | 2012-03-22 | Massachusetts Institute Of Technology | Compositions containing PUFA and methods of use thereof |
| RU2444356C2 (ru) * | 2005-07-08 | 2012-03-10 | Мартек Байосайенсиз Корпорейшн | Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией |
| WO2007059762A1 (de) * | 2005-11-25 | 2007-05-31 | Gisela Susilo | Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid |
| WO2008081934A1 (ja) * | 2006-12-28 | 2008-07-10 | Meiji Dairies Corporation | 乳由来リン脂質を含有する乳幼児脳発達促進剤及びそれを含有する食品組成物 |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| MX2010000224A (es) * | 2007-06-26 | 2010-05-03 | Nutricia Nv | Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26. |
| WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| WO2009057994A1 (en) * | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
| EP2217075A4 (en) * | 2007-11-02 | 2012-01-25 | Massachusetts Inst Technology | URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF |
| MX2010006829A (es) | 2007-12-20 | 2010-09-30 | Nutricia Nv | Producto que contiene nucleotidos/nucleosidos liquidos. |
| CN108324706A (zh) * | 2009-02-02 | 2018-07-27 | 帝斯曼知识产权资产有限公司 | 改善认知功能和降低心率的方法 |
| WO2011133580A1 (en) * | 2010-04-19 | 2011-10-27 | Back Bay Scientific Llc | Use of drugs that activate p2y receptors to enhance synaptogenesis |
| WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| EP2806736A4 (en) * | 2011-10-21 | 2015-10-14 | Omthera Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT |
| WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| CN104144691A (zh) * | 2012-03-02 | 2014-11-12 | N·V·努特里奇亚 | 改善功能突触连通性的方法 |
| WO2013129914A1 (en) * | 2012-03-02 | 2013-09-06 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| WO2014171813A1 (en) | 2013-04-17 | 2014-10-23 | N.V. Nutricia | Nutritional composition for improving brain function in phenylketonuria |
| CN103877144B (zh) * | 2013-05-02 | 2017-02-22 | 杭州耐奇睿生物医药科技有限公司 | 花生衣活性组分的应用及包含该花生衣活性组分的组合物 |
| US20160235778A1 (en) * | 2014-03-13 | 2016-08-18 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| WO2016083362A1 (en) * | 2014-11-25 | 2016-06-02 | Fonden For Helene Elsass Centeret | Composition for improving cognitive functions |
| WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
| WO2017155387A1 (en) | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for supporting memory function and/or cognitive function |
| WO2017167415A1 (en) * | 2016-03-30 | 2017-10-05 | Nestec S.A. | Compositions comprising fatty acids and their use |
| EP4292651A3 (en) * | 2016-06-27 | 2024-03-13 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| CN109689041A (zh) * | 2016-09-29 | 2019-04-26 | 雀巢产品技术援助有限公司 | 作为未患痴呆患者的神经保护剂的ω-3脂肪酸和胆碱 |
| EP3554282A1 (en) * | 2016-12-13 | 2019-10-23 | DSM IP Assets B.V. | Pufa salt formulations (ii) |
| US20210353566A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | The use of choline supplementation as therapy for apoe4-related disorders |
| BR112023001663A2 (pt) | 2020-07-29 | 2023-02-23 | Novamedica Llc | Composição farmacêutica compreendendo memantina e citicolina |
| EP4353261A4 (en) * | 2021-06-09 | 2025-06-18 | Hospital Sant Joan de Deu | Nutraceutical combination and its use in the treatment of neurological diseases |
| CN113577092B (zh) * | 2021-07-30 | 2022-07-01 | 陈玉松 | 一种延缓衰老的含核苷酸的组合物及其制备方法和应用 |
| CN115774059A (zh) * | 2021-09-07 | 2023-03-10 | 中国科学院深圳先进技术研究院 | 一种阿尔兹海默症生物标志物及其筛选方法和应用 |
| TR2021016704A2 (tr) * | 2021-10-26 | 2021-11-22 | Bursa Uludag Ueniversitesi | Üri̇di̇ni̇n ön uyaran aracili i̇nhi̇bi̇syon bozukluğu i̇le seyreden hastaliklarin tedavi̇si̇nde kullanimi |
| WO2023150389A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Compositions and methods for increasing dha availability |
| CN115334384B (zh) | 2022-08-05 | 2025-03-14 | 立臻科技(昆山)有限公司 | 一种移动终端会议音箱 |
| CN119881117A (zh) * | 2023-10-25 | 2025-04-25 | 中国科学院上海营养与健康研究所 | 母乳芥酸检测在评价婴幼儿发育中的用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221784A (en) | 1979-04-05 | 1980-09-09 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lecithin |
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| EP0707487B1 (en) * | 1993-06-09 | 2004-04-14 | Martek Biosciences Corporation | Methods and pharmaceutical compositions useful for treating neurological disorders |
| US20050027004A1 (en) | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| US5492899A (en) * | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
| JPH07143862A (ja) * | 1994-05-06 | 1995-06-06 | Maruha Corp | 脳機能改善効果を有する機能性食品。 |
| EP0831805A1 (en) | 1995-06-07 | 1998-04-01 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
| JPH0975000A (ja) * | 1995-07-07 | 1997-03-25 | Nisshin Oil Mills Ltd:The | 母子栄養用油脂含有飲食物 |
| US6200624B1 (en) | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
| DE19608137A1 (de) | 1996-03-02 | 1997-09-04 | Meyer Lucas Gmbh & Co | Lipid-Zubereitungen für diätetische Zwecke |
| JP3627043B2 (ja) | 1996-04-24 | 2005-03-09 | 明治乳業株式会社 | ｎ−６系列／ｎ−３系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品 |
| CA2261231C (en) | 1996-07-23 | 2012-11-27 | Nagase Biochemicals, Ltd. | Process using ulkenia sp. to prepare docosahexaenoic acid and docosapentaenoic acid |
| US6080787A (en) | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
| HUP0300236A3 (en) | 1997-02-21 | 2003-09-29 | Univ Tennessee Res Corp Knoxvi | Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation |
| JPH10327804A (ja) | 1997-06-04 | 1998-12-15 | Meiji Milk Prod Co Ltd | 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物 |
| JP3731983B2 (ja) | 1997-08-27 | 2006-01-05 | 明治製菓株式会社 | 痴呆犬の夜鳴き改善薬 |
| JP3408958B2 (ja) * | 1997-10-24 | 2003-05-19 | 旭化成株式会社 | 魚介類由来の有用物質を含む組成物およびその有用物質の製造方法 |
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| US7413759B2 (en) | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| ATE374029T1 (de) * | 1998-07-31 | 2007-10-15 | Massachusetts Inst Technology | Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo |
| US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| WO2000012102A1 (en) | 1998-08-31 | 2000-03-09 | Proteotech, Inc. | Blended compositions for treatment of alzheimer's disease and other amyloidoses |
| US6495599B2 (en) | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
| US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| CA2344564C (en) | 2000-09-14 | 2008-07-22 | General Electric Canada Inc. | Graded electric field insulation system for dynamoelectric machine |
| US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| US6541043B2 (en) | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| EP1302196A1 (de) | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Intelligenzfördernde Zahncreme |
| NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6677470B2 (en) | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
| US20040048926A1 (en) | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| PT1542670E (pt) * | 2002-09-24 | 2013-07-11 | Suntory Holdings Ltd | Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável |
| JP2004231585A (ja) | 2002-12-05 | 2004-08-19 | Fancl Corp | 生体内ホモシステインレベル低減用および上昇抑制用組成物 |
| CA2508995A1 (en) | 2002-12-20 | 2004-07-15 | The Mclean Hospital Corporation | Use of cytidine-, creatine-, and adenosine-containing compounds and adenosine-elevating compounds for normalizing sleep/wake cycle, treating a sleep disorder or improving cognitive function |
| CN1203867C (zh) | 2003-03-11 | 2005-06-01 | 刘威 | 精制海狗油在制备防治老年痴呆药中的应用 |
| US7951410B2 (en) | 2003-04-14 | 2011-05-31 | Mead Johnson Nutrition Company | Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid |
| US7867541B2 (en) | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
| EP1670324A1 (en) | 2003-09-26 | 2006-06-21 | Nestec S.A. | Nutritional composition with unsaturated fatty acids and trace elements |
| US8921422B2 (en) | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
| JP2007508315A (ja) | 2003-10-08 | 2007-04-05 | ザ マクレーン ホスピタル コーポレーション | ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法 |
| EP1634599A1 (en) * | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Iimmune stimulatory infant nutrition |
| EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
| US20060247153A1 (en) | 2005-04-29 | 2006-11-02 | Mcmahon Robert J | Method of improving learning and memory in mammals |
| AU2006251562B2 (en) | 2005-05-23 | 2012-03-22 | Massachusetts Institute Of Technology | Compositions containing PUFA and methods of use thereof |
| US7829126B2 (en) | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
-
2006
- 2006-05-23 AU AU2006251562A patent/AU2006251562B2/en active Active
- 2006-05-23 CA CA2645645A patent/CA2645645C/en not_active Expired - Lifetime
- 2006-05-23 AU AU2006251569A patent/AU2006251569B2/en active Active
- 2006-05-23 CN CN201610212919.6A patent/CN105663151A/zh active Pending
- 2006-05-23 BR BRPI0613274-0A patent/BRPI0613274A2/pt not_active Application Discontinuation
- 2006-05-23 PT PT67708628T patent/PT1888081T/pt unknown
- 2006-05-23 NZ NZ600740A patent/NZ600740A/en unknown
- 2006-05-23 NZ NZ563659A patent/NZ563659A/en active IP Right Revival
- 2006-05-23 WO PCT/US2006/019778 patent/WO2006127627A2/en not_active Ceased
- 2006-05-23 DK DK06770862.8T patent/DK1888081T3/en active
- 2006-05-23 EP EP06770862.8A patent/EP1888081B1/en not_active Expired - Lifetime
- 2006-05-23 US US11/920,914 patent/US10525071B2/en active Active
- 2006-05-23 ES ES06770871T patent/ES2624702T5/es not_active Expired - Lifetime
- 2006-05-23 HU HUE06770862A patent/HUE031206T2/en unknown
- 2006-05-23 NZ NZ563660A patent/NZ563660A/xx unknown
- 2006-05-23 WO PCT/US2006/019766 patent/WO2006127620A2/en not_active Ceased
- 2006-05-23 CA CA2645647A patent/CA2645647C/en not_active Expired - Lifetime
- 2006-05-23 EP EP06770871.9A patent/EP1909801B2/en not_active Expired - Lifetime
- 2006-05-23 US US11/920,915 patent/US10086009B2/en active Active
- 2006-05-23 PL PL06770862T patent/PL1888081T3/pl unknown
- 2006-05-23 JP JP2008513596A patent/JP5566604B2/ja not_active Expired - Fee Related
- 2006-05-23 BR BRPI0613303A patent/BRPI0613303A8/pt not_active Application Discontinuation
- 2006-05-23 ES ES06770862.8T patent/ES2615521T3/es not_active Expired - Lifetime
- 2006-05-23 JP JP2008513592A patent/JP5566603B2/ja not_active Expired - Lifetime
- 2006-05-23 EP EP16171448.0A patent/EP3090740A1/en not_active Withdrawn
-
2011
- 2011-05-20 RU RU2011120440/15A patent/RU2603470C2/ru active
-
2014
- 2014-04-23 JP JP2014088988A patent/JP5823564B2/ja not_active Expired - Lifetime
-
2018
- 2018-10-01 US US16/148,546 patent/US10736912B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400105B2 (en) | Anti-inflammatory properties of marine lipid compositions | |
| JP2008542280A5 (enExample) | ||
| JP5566603B2 (ja) | Ｐｕｆａを含有する組成物及びそれを使用した方法 | |
| van Wijk et al. | Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination | |
| KR101833772B1 (ko) | 고도불포화 지방산 유도체의 의약으로서 용도 | |
| BRPI0415744B1 (pt) | uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional | |
| BRPI0714904A2 (pt) | composiÇço contendo cdp-colina, e seus mÉtodos de uso | |
| Cansev | Synaptogenesis: Modulation by availability of membrane phospholipid precursors | |
| WO2015115885A1 (en) | Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly | |
| RU2007147952A (ru) | Композиции, содержащие полиненасыщенные жирные кислоты (пнжк), и способы их применения | |
| JP5158715B2 (ja) | 平滑筋収縮抑制剤 | |
| JP7579266B2 (ja) | 抗炎症性化合物のための構造化された分子ベクター及びその使用 | |
| AU2012203650B2 (en) | Compositions containing PUFA and methods of use thereof | |
| US20080070870A1 (en) | Use of omega-3 rich phospholipids in the area of cognitive function | |
| DE202017104119U1 (de) | Präparat und Anwendung zur Aufrechterhaltung kognitiver Fähigkeiten von Menschen, insbesondere für unter einer Verminderung ihrer kognitiven Fähigkeiten leidende Menschen und/oder als Prophylaxe |